Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 288 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
18 Years and older
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Conditions
Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
aflibercept, High-dose aflibercept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
84
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 78 more
Conditions
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser
Drug · Behavioral · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
56
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 46 more
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Home vision monitoring using myVisionTrack®
Device
Lead sponsor
Vital Art and Science Incorporated
Industry
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Dallas, Texas
Conditions
Diabetic Macular Edema, Vitrectomy
Interventions
Dexamethasone
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of Care, Macugen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Conditions
Diabetic Macular Edema
Interventions
KVD001 Injection
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more
Completed Phase 3 Interventional Results available

Treatment for CI-DME in Eyes With Very Good VA Study

NCT01909791
Conditions
Diabetic Macular Edema
Interventions
Prompt Laser, Prompt aflibercept, Deferred laser, Deferred aflibercept
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
100
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more
Conditions
Diabetic Macular Edema
Interventions
RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
Genetic · Biological
Lead sponsor
Sierra Eye Associates
Other
Eligibility
25 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Reno, Nevada
Conditions
Diabetic Retinopathy
Interventions
Peribulbar Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Macular Edema
Interventions
Aflibercept, Faricimab, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more
Conditions
Diabetic Retinopathy
Interventions
Nepafenac ophthalmic suspension, 0.1% (NEVANAC®), Nepafenac ophthalmic suspension vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Diabetic Macular Edema
Interventions
EC-104 high dose, EC-104 low dose, Dexamethasone intravitreal implant
Drug
Lead sponsor
Eclipse Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Terminated Not applicable Interventional Accepts healthy volunteers

Adaptive Optics for Ophthalmic Technologies

NCT02826655
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
WF-AO-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Diabetic Macular Edema
Interventions
KVD001 Injection, Sham Procedure
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 28 more
Conditions
Diabetic Macular Edema
Interventions
bevacizumab, PASCAL Endpoint Management (EpM) laser treatment
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Results available

Ranibizumab and Bevacizumab for Diabetic Macular Edema

NCT01610557
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab, Bevacizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, Other Retinal Disorders
Interventions
Not listed
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Bellaire, Texas • Katy, Texas • The Woodlands, Texas
Conditions
Retinal Vasculitis
Interventions
aflibercept 2mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
290,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Conditions
Diabetes, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
OCT imaging
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Wellfleet, Massachusetts • Syracuse, New York + 1 more
Conditions
Macular Edema
Interventions
abicipar pegol, ranibizumab, sham procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
19 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Gilbert, Arizona • Abilene, Texas